Literature DB >> 29155047

Novel mosaic variants in two patients with Cornelia de Lange syndrome.

Jelena Pozojevic1, Ilaria Parenti1, Luitgard Graul-Neumann2, Sara Ruiz Gil1, Erwan Watrin3, Kerstin S Wendt4, Ralf Werner5, Tim M Strom6, Gabriele Gillessen-Kaesbach7, Frank J Kaiser8.   

Abstract

Cornelia de Lange syndrome (CdLS) is a dominantly inherited developmental disorder caused by mutations in genes that encode for either structural (SMC1A, SMC3, RAD21) or regulatory (NIPBL, HDAC8) subunits of the cohesin complex. NIPBL represents the major gene of the syndrome and heterozygous mutations can be identified in more than 65% of patients. Interestingly, large portions of these variants were described as somatic mosaicism and often escape standard molecular diagnostics using lymphocyte DNA. Here we discuss the role of somatic mosaicism in CdLS and describe two additional patients with NIPBL mosaicism detected by targeted gene panel or exome sequencing. In order to verify the next generation sequencing data, Sanger sequencing or pyrosequencing on DNA extracted from different tissues were applied. None of the pathogenic variants was originally detected by Sanger sequencing on blood DNA. Patient 1 displays an unusual combination of clinical features: he is cognitively only mildly affected, but shows severe limb reduction defects. Patient 2 presents with a moderate phenotype. Interestingly, Sanger sequencing analysis on fibroblast DNA of this patient did not detect the disease-causing variant previously observed on the same DNA sample by exome sequencing. Subsequent analyses could confirm the variants by Sanger sequencing on buccal mucosa DNA. Notably, this is the first report of a higher mutational load in buccal mucosa than in fibroblast cells of a CdLS patient. Detection of low-level mosaicism is of utmost importance for an accurate molecular diagnosis and a proper genetic counseling of patients with a clinical diagnosis of CdLS. Next-generation sequencing technologies greatly facilitate the detection of low-level mosaicism, which might otherwise remain undetected by conventional sequencing approaches.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cornelia de Lange syndrome; Mosaicism; NIPBL

Mesh:

Substances:

Year:  2017        PMID: 29155047     DOI: 10.1016/j.ejmg.2017.11.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  Mosaic Intronic NIPBL Variant in a Family With Cornelia de Lange Syndrome.

Authors:  Natalia Krawczynska; Alina Kuzniacka; Jolanta Wierzba; Ilaria Parenti; Frank J Kaiser; Bartosz Wasag
Journal:  Front Genet       Date:  2018-07-13       Impact factor: 4.599

Review 2.  Cornelia de Lange syndrome: from molecular diagnosis to therapeutic approach.

Authors:  Patrizia Sarogni; Maria M Pallotta; Antonio Musio
Journal:  J Med Genet       Date:  2019-11-08       Impact factor: 6.318

3.  Evaluating Face2Gene as a Tool to Identify Cornelia de Lange Syndrome by Facial Phenotypes.

Authors:  Ana Latorre-Pellicer; Ángela Ascaso; Laura Trujillano; Marta Gil-Salvador; Maria Arnedo; Cristina Lucia-Campos; Rebeca Antoñanzas-Pérez; Iñigo Marcos-Alcalde; Ilaria Parenti; Gloria Bueno-Lozano; Antonio Musio; Beatriz Puisac; Frank J Kaiser; Feliciano J Ramos; Paulino Gómez-Puertas; Juan Pié
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

4.  Clinical relevance of postzygotic mosaicism in Cornelia de Lange syndrome and purifying selection of NIPBL variants in blood.

Authors:  Ana Latorre-Pellicer; Marta Gil-Salvador; Ilaria Parenti; Cristina Lucia-Campos; Laura Trujillano; Iñigo Marcos-Alcalde; María Arnedo; Ángela Ascaso; Ariadna Ayerza-Casas; Rebeca Antoñanzas-Pérez; Cristina Gervasini; Maria Piccione; Milena Mariani; Axel Weber; Deniz Kanber; Alma Kuechler; Martin Munteanu; Katharina Khuller; Gloria Bueno-Lozano; Beatriz Puisac; Paulino Gómez-Puertas; Angelo Selicorni; Frank J Kaiser; Feliciano J Ramos; Juan Pié
Journal:  Sci Rep       Date:  2021-07-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.